SBI Securities’s Biodexa Pharmaceuticals BDRX Stock Holding History

SBI Securities’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12	Sell	2 -2	-50%	-$23	﹤0.01%	3985
2026 Q2	$84	Hold	4	–	–	﹤0.01%	3546
2026 Q1	$93	Buy	4 +1	+33%	+$56	﹤0.01%	3423
2025 Q4	$229	Hold	3	–	–	﹤0.01%	3168
2025 Q3	$765	Sell	3 -11	-79%	-$3.16K	﹤0.01%	2804
2025 Q2	$4.9K	Buy	+14	New	+$7.14K	﹤0.01%	1993
2025 Q1	–	Hold	0	–	–	–	4108
2024 Q4	–	Hold	0	–	–	–	4005

Other funds holding BDRX

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

SBI Securities's BDRX Position: Q3 2026 in Review

SBI Securities reduced its Biodexa Pharmaceuticals (BDRX) stake by 50% in Q3 2026, selling an estimated $23 and leaving 2 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #3985.

SBI Securities first reported a position in BDRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.9K in Q2 2025. 3 funds tracked by Wall St. Rank hold BDRX as of Q3 2026.

SBI Securities held 2 shares of Biodexa Pharmaceuticals worth $12 as of Q3 2026.
SBI Securities sold 2 Biodexa Pharmaceuticals shares in Q3 2026, an estimated $23.
Biodexa Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3985 holding.
SBI Securities first reported a position in Biodexa Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
SBI Securities's Biodexa Pharmaceuticals position peaked at $4.9K in Q2 2025.
3 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.